MyoKardia, Inc.
DelistedCIK 1552451fmd_1RBN8VNVFTTVPSQ7XEY6MPCHTRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2020, 28 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 42 | 11 | 34 | 0 |
| Research and development | 12 | 18 | 28 | 36 | 48 | 69 | 146 |
| Selling, general and administrative | – | – | – | – | 22 | 38 | 62 |
| Total operating expenses | 14 | 23 | 37 | 53 | 70 | 107 | 288 |
| Operating income | (14) | (17) | (23) | (11) | (59) | (74) | (288) |
| Income tax expense | – | 0 | 0 | 0 | 0 | – | – |
| Net income | (13) | (17) | (23) | (10) | (57) | (68) | (276) |
| Net income to common shareholders | (14) | (20) | (28) | (13) | (46) | – | – |